EyePoint Pharmaceuticals posted an updated investor presentation on April 13, 2026, highlighting DURAVYU's Phase 3 clinical progress in wet AMD and DME, with topline data anticipated beginning in mid-2026 and full enrollment of DME trials expected in the third quarter of 2026.
Key takeaways
DURAVYU Phase 3 wet AMD trials LUGANO and LUCIA are fully enrolled, with topline 56-week data expected for LUGANO in mid-2026 and LUCIA anticipated shortly after.
DURAVYU Phase 3 DME trials COMO and CAPRI are underway, with full enrollment anticipated in the third quarter of 2026.
The company reported an unaudited estimate of over $220 million in cash and investments as of March 31, 2026, supporting its cash runway into the fourth quarter of 2027.
DURAVYU has demonstrated a favorable safety profile in over 190 patients across four clinical trials, with no DURAVYU-related ocular or systemic severe adverse events.
The combined global market opportunity for wet AMD and DME is over $15 billion, representing more than 80% of the total branded retinal market.